In the not so distant far, assays of CD4 T-cells derived from mediastinal lymph nodes might identify patients with IPF at greater risk for progression or lung cancer development and patients more likely to experience benefit from targeted immunotherapy. Here, CD4 is linked to idiopathic pulmonary fibrosis.